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BACKGROUND: Microsatellite instability (MSI) is commonly screened using a panel of two mononucleotide and three dinucleotide
repeats as recommended by a consensus meeting on MSI tumours held at the National Cancer Institute (Bethesda, MD, USA).
According to these recommendations, tumours are classified as MSI-H when at least two of the five microsatellite markers show
instability, MSI-L when only one marker shows instability and MSS when none of the markers show instability. Almost all MSI-H
tumours are characterised by alterations in one of the four major proteins of the mismatch repair (MMR) system (MLH1, MSH2,
MSH6 or PMS2) that renders them MMR deficient, whereas MSI-L and MSS tumours are generally MMR proficient. However,
tumours from patients with a pathogenic germline mutation in MSH6 can sometimes present an MSI-L phenotype with the NCI
panel. The MSH6 protein is not involved in the repair of mismatches of two nucleotides in length and consequently the three
dinucleotide repeats of the NCI panel often show stability in MSH6-deficient tumours.
METHODS: A pentaplex panel comprising five mononucleotide repeats has been recommended as an alternative to the NCI panel to
determine tumour MSI status. Several studies have confirmed the sensitivity, specificity and ease of use of the pentaplex panel;
however, its sensitivity for the detection of MSH6-deficient tumours is so far unknown. Here, we used the pentaplex panel
to evaluate MSI status in 29 tumours known to harbour an MSH6 defect.
RESULTS: MSI-H status was confirmed in 15 out of 15 (100%) cases where matching normal DNA was available and in 28 out of
29 (97%) cases where matching DNA was not available or was not analysed.
CONCLUSION: These results show that the pentaplex assay efficiently discriminates the MSI status of tumours with an MSH6 defect.
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Human tumours with a deficient DNA mismatch repair (MMR)
system represent a subset of tumours with distinctive features at
both the molecular and clinical levels. They are relatively frequent
and account for 10–15% of common cancer types such as those
arising in the colon, stomach and endometrium (Boland et al,
1998). The result of defective DNA MMR is the occurrence of
frequent insertion–deletion mutations, especially in short repeti-
tive DNA sequences called microsatellites. Tumours showing such
mutations are therefore referred to as having microsatellite
instability (MSI) (Boland et al, 1998). At the clinical level, MSI
tumours are known to have better prognosis than non-MSI
(or MSS for microsatellite stable) tumours (Popat et al, 2005) and
may respond differently to adjuvant chemotherapy (Ribic et al,
2003). In most sporadic MSI tumours, the MMR defect arises
because of the failure to express the MLH1 gene due to somatic
hypermethylation of its promoter (Kane et al, 1997). MSI tumours
also arise in families with a genetic predisposition known as Lynch
syndrome (Lynch and Lynch, 2004). Predisposed members of these
families contain a germline mutation in one of the MMR genes,
usually MSH2 or MLH1 and less frequently MSH6 or PMS2
(Peltoma¨ki, 2005). Screening to determine defective MMR status is
becoming increasingly common, especially with a view to identify
families with Lynch syndrome. Two different strategies are used
for this purpose. Immunohistochemistry (IHC) is used to detect
the lack of expression of one or more MMR proteins, whereas MSI
analysis is used to detect instability in microsatellite repeats. Pros
and cons are inherent to either strategy (Shia, 2008; Zhang, 2008)
and will not be discussed here, other than to state that these
methods provide complementary information.
Received 28 July 2010; revised 8 October 2010; accepted 14 October
2010; published online 16 November 2010
*Correspondence: Dr R Hamelin; E-mail: Richard.Hamelin@inserm.fr
British Journal of Cancer (2010) 103, 1840 – 1845
& 2010 Cancer Research UK All rights reserved 0007 – 0920/10
www.bjcancer.com
M
o
le
c
u
la
r
D
ia
g
n
o
stic
s
Following an NCI consensus meeting on MSI tumours, a panel
of five microsatellites (two mononucleotide repeats and three
dinucleotide repeats) was proposed to standardise the classifica-
tion of MSI status in tumours (Boland et al, 1998). By comparing
amplified tumour DNA profiles with matching normal DNA, a
tumour is classified as MSI-H when it shows instability in at least
two of the five markers and MSI-L or MSS when it shows
instability at one or none of the markers, respectively (Boland et al,
1998). MSI-L tumours usually show instability at only one of the
three dinucleotide markers and their morphological and clinical
phenotype is indistinguishable from MSS tumours (Laiho et al,
2002). However, tumours that have a deficiency in MSH6 often do
not show instability in dinucleotide repeats and therefore risk
being classified as MSI-L or even MSS when analysed with the NCI
panel containing only two potentially unstable mononucleotide
repeats (Verma et al, 1999; Wu et al, 1999).
At a second consensus meeting, mononucleotide repeats were
recognised as being more specific and sensitive for the determina-
tion of MSI status than dinucleotide repeats (Umar et al, 2004).
A panel of five mononucleotide repeats was proposed and the
conditions for their amplification in a single pentaplex PCR were
described (Suraweera et al, 2002). However, the efficiency of the
pentaplex panel for the detection of MMR-deficient tumours with
an MSH6 mutation is currently unknown and is the subject of the
present investigation. Germline mutations in MSH6 are relatively
rare and estimated to account for 5–10% of Lynch syndrome
cases. These in turn represent 2–7% of all colorectal cancers,
indicating that germline mutations in MSH6 account forB0.3% of
cases. In the present study, 29 tumour samples with MSH6
deficiency were collected from three Dutch and one French cancer
centres and evaluated for MSI status using the pentaplex panel.
MATERIALS AND METHODS
Tissue specimens
Formalin-fixed, paraffin-embedded tumour and matching normal
(when available) samples were obtained from three Dutch
(Radboud University Nijmegen Medical Centre, Nijmegen, the
Netherlands; University Medical Center Groningen, Groningen,
the Netherlands; Josephine Nefkens Institute, Erasmus MC,
Rotterdam, the Netherlands) and one French cancer centre
(Hoˆpital Saint-Antoine, Paris, France). All patients gave informed
consent for the analysis. MMR-deficient protein(s) were deter-
mined by IHC analysis in all cases. As it is well established that
MSI tumours deficient in MSH2 also show loss of MSH6
expression, the current study investigated only tumours that
showed loss of MSH6 expression alone. A total of 29 tumours
arising from different sites (colon, endometrium and urothelium)
were selected, of which matching normal DNA was available for 15
cases. The fixation procedure, length of storage and DNA
extraction method differed considerably between samples due to
their different origin. Germline MSH6 mutations were determined
in most cases from peripheral blood samples using standard
sequencing methods. DNA from 10 MSS tumours, and their
matching normal DNA, was also analysed.
Microsatellite analysis
Two versions of the pentaplex assay were used here to analyse the
Dutch samples as previously described. The older version
comprises the NR-21, BAT-26, BAT-25, NR-24 and NR-22
mononucleotide repeats with average PCR product sizes in
Caucasian individuals of 103, 120, 124, 132 and 142 bp, respectively
(Suraweera et al, 2002). The newer version of the assay comprises
the NR-27, NR-21, NR-24, BAT-25 and BAT-26 repeats with
average PCR product sizes in Caucasians of 87, 107, 126, 148 and
179 bp, respectively (Buhard et al, 2004, 2006). The new conditions
were designed to avoid interference between different dyes during
the laser scanning, and this assay is generally more convenient for
use with high quality DNA extracted from frozen tissue samples.
However, the larger PCR products of the new assay compared to
the older pentaplex assay makes it more susceptible to DNA
quality. Samples from the Saint-Antoine hospital were analysed
using a commercial MSI detection kit (Promega France, Charbon-
nie`res-les-Bains, France), derived from the pentaplex assay and
composed of NR-21, BAT-26, BAT-25, NR-24 and Mono-27. The
latter mononucleotide repeat (localised within the MAP4K3 gene)
is different to NR-27 (localised within the 50 UTR of the inhibitor of
apoptosis protein 1 gene). Tumours were defined as MSI when
three or more of the five markers showed instability, regardless the
pentaplex version that was used (Suraweera et al, 2002; Buhard
et al, 2006). In the absence of comparison with matching normal
DNA, these very stringent conditions avoid the occurrence of rare
false-positive cases due to some ethnic variants.
RESULTS
Pentaplex amplification efficiency depends on PCR
product size
We first analysed samples from Nijmegen and Groningen (tumour
DNA together with matching normal controls when available),
with the new version of the pentaplex assay in which the size of the
normal PCR products ranged from 87 to 179 bp (Buhard et al,
2006). Successful amplification of all five markers was achieved in
only 51% of samples (Figure 1A). Not surprisingly, successful
amplification was more commonly observed for the markers
associated with shorter PCR products. The success of PCR
amplification is highly dependent on sample fixation, length of
storage and method of DNA extraction. As these conditions were
quite variable for the different samples, it was decided to use the
older pentaplex assay version in which the PCR product sizes are
smaller (range 103–142 bp) (Suraweera et al, 2002). With this
assay, successful amplification of the five markers was obtained in
90% of cases regardless of their origin from tumour or normal
matching DNA (Figure 1B). DNA samples from the third Dutch
series (Rotterdam) were therefore amplified directly using the
older pentaplex assay, and all results described below on the Dutch
samples were obtained using this assay.
PCR profiles of normal DNA
The size of all PCR products was determined individually using
Genescan software and was rounded up or down to the next
integer. Amplification for all five markers was achieved in 23 out of
25 (92%) of the normal tissue samples. The size variation observed
was 103–105 bp (NR-21), 116–118 bp (BAT-26), 122–124 bp
(BAT-25), 130–131 bp (NR-24) and 141–142 bp (NR-22). These
values define the quasi-monomorphic variation range (QMVR) for
each marker in the germline DNA analysed in this study. They are
slightly different from the values reported in our original
manuscript. We have already shown that this is due to the use of
different instrumentation and reagents (Buhard et al, 2006). These
factors were not identical 8 years apart. The total variation range
(TVR) as defined by the sum of the sizes of the five markers was
613–619 bp for normal DNA in the present analysis (Figure 2).
None of the markers in any of the individuals in this study showed
an allelic variant that was clearly outside of the QMVR. This has
been found on rare occasions in the worldwide populations
(Buhard et al, 2006). Although the ethnic origin of the Dutch
patients analysed here was unknown, the majority were likely to be
Caucasian. If present in a series, variant alleles should not be
included for QMVR and TVR calculation in normal DNA.
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PCR profiles of DNA from MSS tumours
Amplification of the five markers was achieved in all 10 MSS
tumour samples and matching normal DNA. The size of PCR
products obtained with tumour DNA showed no size variation
compared to those obtained from matching normal DNA. Without
referring to matching normal DNA, each marker from each
tumour was then assessed in terms of whether it was inside or
outside the normal QMVR. The sum of the size of each
amplification product was also compared to the TVR from normal
DNA. Markers were always within the QMVR and the total size of
the five amplified products varied from 615 to 617 bp. These were
all within the normal TVR of 613–619 bp as defined above
(Figure 2). As expected, MSS tumours could thus be classified
without the need to refer to profiles from matching normal DNA.
These results confirm those previously obtained with the original
version of the pentaplex assay on 62 MSS gastrointestinal primary
tumours and cell lines (Suraweera et al, 2002).
PCR profiles of DNA from tumours with MSH6 deficiency
Of the 23 MSH6-defective tumour samples of Dutch origin,
matching normal DNA was available for 15 cases. Successful
amplification of the five markers was achieved for both the tumour
and normal DNA in all 15 cases. Differences between tumour and
matching normal DNA in terms of the size of PCR products for each
marker are shown in Table 1A. Fourteen cases showed instability in
all five markers, whereas the remaining case showed instability in
four of the five markers. In some cases, the instability was only 1 bp
in size. The non bold values in Table 1a indicate markers that were
within the QMVR, as defined above for the normal DNA. These
markers would have been recorded as stable in the absence of
comparison with matching normal DNA. Bold values indicate
markers that were outside the normal QMVR and would have been
recorded as unstable, even in the absence of comparison with
matching normal DNA. Thus, if analysis was performed without
reference to matching normal DNA, instability at five or four
markers was detected in 10 and five cases, respectively.
Normal matching DNA was not available or did not amplify
correctly for eight additional tumours. We thus compared the size
of the amplified products to the QMVR (Table 1B). Markers were
considered unstable when they fell outside QMVR values (bold
values) and stable when they were within QMVR values (non bold
values). These eight MSH6-deficient tumours showed instability at
five markers (three cases), four markers (four cases) and three
markers (one case). As MSI was defined as three or more of the
five markers showing instability, all eight tumours were considered
to show MSI.
Using the original pentaplex assay, the MSH6-deficient samples
thus displayed a total PCR product size of 575–607 bp (Figure 2,
grey columns). This was clearly different to the total size observed
for MSS tumours (Figure 2, black columns) and to the TVR of
normal DNA (Figure 2, white columns; 613–619 bp). MSI tumours
could be roughly divided into two groups showing total sizes of
575–593 bp and 598–607 bp. This subclassification showed some
relation to tumour localisation (colon/small bowel vs endome-
trium/urothelium). Although not statistically significant (P¼ 0.09,
Fisher’s exact test), this result confirms the already published
observation that endometrial MSI tumours show a smaller
amplitude of instability compared to colorectal MSI tumours
(Wong et al, 2006).
Finally, we examined six cases from patients who underwent
surgery for colorectal cancer at Saint-Antoine Hospital and whose
tumours showed loss of MSH6 expression alone. These were
evaluated for MSI using a commercial kit (Promega) that was
based on the pentaplex assay (Table 1C). In the absence of normal
DNA, the QMVR for the five markers in this kit was defined by the
size of the PCR products in a series of about 1000 MSS tumours
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Figure 2 Total size of amplified markers using the old pentaplex assay.
The sum of the sizes of the five PCR products obtained with the
old pentaplex assay is indicated for normal DNA (white columns), DNA
extracted from MSS tumours (black columns) or DNA extracted from
MSH6-defective tumours (grey columns). In the latter case, light grey
corresponds to tumours obtained from colon, and dark grey to tumours
from the endometrium or urothelium.
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Figure 1 Comparative analysis of the amplification efficiency with old
and new versions of the pentaplex assay. DNA extracted from 31 tumours
(21 with an MSH6 defect and 10 classified as MSS) and from 26 matching
normal tissues (Nijmegen and Groningen series) were analysed with new
(A) or old (B) versions of the pentaplex assay. In each case, the percentage
of samples that showed successful amplification of 0–5 of the markers is
indicated: white columns, normal DNA; black columns, tumour DNA; grey
columns, all samples. Three tumours and one normal DNA showed
amplification of none or only one of the markers with both the old and
new pentaplex assay versions and were excluded from further analysis.
DNA samples that successfully amplified at four or five markers using the
old assay were kept for analysis even if the amplification was not successful
with the new assay version.
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(as determined by IHC analysis), excluding obvious variant alleles
due to ethnicity (not shown). The QMVR was 99–103 bp (NR-21),
114–116 bp (BAT-26), 121–126 bp (BAT-25), 130–133 bp (NR-24)
and 150–154 bp (Mono-27), while the TVR was 614–632 bp. Three
of the six MSH6-deficient samples had at least four of the markers
whose size was outside the QMVR. These showed total values
of 591, 597 and 604 bp. Two tumours had two markers outside the
QMVR and showed total values of 610 and 613 bp, which were still
lower than the normal TVR. Although not obviously MSI
according to standard criteria, the results obtained with these
two samples drew attention to the fact that further investigation
was required to correctly define their MSI status. Although it
showed a relatively low TVR (614 bp), the final sample did not
present any characteristics to indicate it had MSI.
DISCUSSION
Determination of the MSI status of tumours is performed routinely
in most cancer centres due to the clinical importance of this
phenotype. For this purpose, IHC has an advantage over MSI
screening in that it can indicate which MMR gene is altered. MSI
analysis can also be more time- and labour-consuming than IHC.
However, on some occasions, germline missense mutations in an
MMR gene can lead to functional inactivation of the protein
without affecting its stability and therefore its expression level.
Our view is that IHC and MSI screening methods provide
complementary information regarding defective MMR and should
therefore be performed in parallel, although this is still a matter of
ongoing debate.
The NCI panel of markers proposed at an international
consensus meeting served as an important step in standardising
the MSI determination process (Boland et al, 1998). Nevertheless,
at a follow-up NCI workshop, it was widely acknowledged that
dinucleotide microsatellites, of which there are three in the NCI
panel, were less sensitive and specific than mononucleotide repeats
for the determination of MSI status (Umar et al, 2004). One of the
major objections levelled against the original NCI panel concerned
the screening of tumours with defective MSH6, one of the four
major MMR genes responsible for Lynch syndrome. The MSH6
protein participates in the correction of base–base mismatches
and single nucleotide deletions/insertions, but not in the repair of
larger deletion/insertion loops (Drummond et al, 1995). Instability
involves one unit of repeated sequences and dinucleotide repeats
are unstable in units of 2 bp. Hence, the corresponding mismatches
are not recognised by the MutSa complex (MSH2/MSH6), but by
Table 1 Sizes of PCR products obtained with the pentaplex assay in MSH6-defective tumours
(A)
ID DNA MSH6 mutation NR21 BAT26 BAT25 NR24 NR22 Total
Y708-D4826a Colon c.2672delT,2674delT (p.Ile891fsX8) 9 12 8 3 8 575
Y708-D4824a Colon c.2672delT,2674delT (p.Ile891fsX8) 9 8 8 3 7 576
M03-121Bb Colon ND 9 3 8 7 4 576
K4-033T Colon c.3514dup (p.Arg1172fsX5) 9 9 8 3 5 582
K120T Colon c.651dup (p.Lys218X) 7 10 4 4 3 589
K97T Colon c.651dup (p.Lys218X) 4 9 4 6 3 591
Y3039-D7713 Colon c.1190_1191del (p.Tyr397CysfsX3) 4 6 5 5 1 598
K5-034T Colon c.261?_457+?dup (duplication exon 2) 7 3 0 4 4 599
K5-063T Colon c.3438+1G4A (splicing site mutation) 4 6 3 2 3 599
K3-120T Colon c.3273dup (p.Lys1092X) 3 4 3 3 1 600
K5-145T Endometrium c.3261del (p.Phe1088SerfsX2) 3 3 5 2 3 602
K6-097T Colon c.4001G4A (p.Arg1334Gln splicing site mutation) 4 4 1 4 1 603
Y37-D2057 Endometrium c.651dup (p.Lys218X) 3 2 4 2 2 603
K3-019T Urothelium c.1?_457+?del (deletion exon 1 and 2) 4 2 1 1 4 604
M03-121Cb Endometrium ND 3 5 3 1 1 604
(B)
ID DNA MSH6 mutation NR21 BAT26 BAT25 NR24 NR22 Total
Y88-D3251 Colon c.3263dupT (p.Glu1090ArgfsX3) 99 108 118 120 138 583
M04-293B Endometrium ND 98 111 115 127 136 587
K4-029T Small bowel c.2815C4T (p.Gln939X) 99 111 119 127 136 592
Y1-D3737c Urothelium c.3772C4T (p.Gln1258X) 99 108 118 131 137 593
Y725-D940 Colon c.651dup (p.Lys218X) 96 108 120 131 138 593
M02-285B Endometrium c.1614_1616delTCinsAG (p.Tyr538X) 103 112 118 127 139 599
Y1-D3736c Urothelium c.3772C4T (p.Gln1258X) 104 114 121 129 138 606
M04-87T Endometrium c.1784del (p.Leu595TyrfsX15) 102 114 123 130 138 607
(C)
ID DNA MSH6 mutation NR21 BAT26 BAT25 NR24 Mono27 Total
06R0110 Colon c.560dup (p.Ile188AspfsX2) 96 109 118 123 145 591
07D280 Colon ND 94 110 120 126 147 597
07G8474 Colon ND 95 110 120 131 148 604
08G664 Colon ND 99 110 120 130 151 610
07G8779 Colon c.3264_3270del (p.Glu1090LysfsX23) 101 114 120 131 147 613
01G5462 Colon ND 99 114 121 130 150 614
Abbreviation: ND¼ not done. 1a and 1b show Dutch tumour series analysed with the old pentaplex assay in comparison to matching normal DNA (1a) or to normal DNA
QMVR (1b). 1c shows French tumour series analysed with the commercial MSI kit and compared to normal DNA QMVR. In each case, the total size of amplified markers is
indicated and the tumours are classified according to the increasing size of these totals. Bold values indicate PCR products that were classified as showing instability, even if they
were not compared to matching normal DNA (in 1a), as they were outside the normal QMVR. Non bold values indicate PCR products within the normal QMVR and classified as
showing no instability when not compared to matching normal DNA. a,b,cDifferent tumours from the same patient. Germline MSH6 mutations are indicated in most cases.
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the MutSb complex (MSH2/MSH3). Consequently, tumours with
MSH6 deficiency are generally stable at dinucleotide repeats,
and their MSI status is therefore debatable. There is clearly a
need for further work to identify markers that are specific for
MSH6-deficient tumours.
Our group recently proposed a panel of five mononucleotide
repeats to determine MSI and has described the conditions
necessary to amplify these markers in a single pentaplex PCR
(Suraweera et al, 2002; Buhard et al, 2006). The sensitivity and
specificity of this pentaplex assay, together with its ease of use, has
led to its widespread adoption for the determination of MSI status
in tumours (Murphy et al, 2006; Xicola et al, 2007; Goel et al,
2010). Preliminary data had suggested that MSH6-deficient
tumours could be detected using mononucleotide repeats, but
these studies were performed with a limited number of markers
and tumours (Verma et al, 1999; Berends et al, 2002; Kets et al,
2006; Mead et al, 2007). The present study represents the first
systematic analysis of a large series of MSH6-deficient tumours
using the five mononucleotide repeats that comprise the pentaplex
assay.
Our study was restricted to tumour samples that showed a
deficiency in MSH6 expression only, as identified by IHC. These
tumours are relatively rare and were obtained from four different
cancer centres in the Netherlands and France. Due to their diverse
origins, DNA extracted from these samples was not always of
sufficient quality to allow amplification of relatively large PCR
products. The original version of the pentaplex assay involving
smaller PCR products was therefore used to evaluate MSI status.
The five markers of the assay (or a commercial kit based on the
assay) were amplified and their size was evaluated in 29 MSH6-
defective tumour samples. The assay demonstrated MSI-H status
in 15 out of 15 cases (100%), in which matching normal DNA was
available, with instability in at least four of the five markers.
When the pentaplex assay conditions were originally described,
these markers were shown to be quasi-monomorphic in normal
DNA from most populations worldwide (Buhard et al, 2006). In the
absence of matching normal DNA, MSI-H status was classified
when tumours showed at least three of the five markers with sizes
outside the QMVR deduced from a large series of unrelated normal
DNA. These conditions are more stringent than those for the
NCI panel of markers, where tumours are considered MSI-H
if they show instability in at least two of the five markers
(Boland et al, 1998). At the same time, they avoid the occurrence of
rare false-positive cases due to possible ethnic variants. According
to this rule, 26 out of 29 (89.5%) of the MSH6-defective samples
evaluated in the present study were classified as MSI-H under
conditions in which the matching normal DNA was not available
or was not analysed. Two of the remaining cases showed instability
at two markers and hence would not have been classified as MSI,
although they would have attracted attention due to the larger than
normal ‘stuttering’ observed in the three ‘stable’ markers. The final
tumour showed no signs of instability in the five markers,
probably because the tumour content of the sample was below
5–10%, the known limit of detection in these conditions
(Brennetot et al, 2005). Unfortunately, additional material was
not available for this patient.
The total size of the five PCR products obtained using the
original pentaplex assay or commercial kit was calculated for
each MSH6-deficient tumour in order to compare it with the TVR
observed in normal DNA. In 28 out of 29 cases (96.5%), these totals
were outside the normal TVR, indicating a positive MSI status for
these samples.
It is generally considered that most, but not all tumours from
Lynch family members are MSI-H. False-negative cases may be due
to the use of NCI panel markers, particularly for MSH6-defective
samples. The pentaplex assay used here is likely to contain the
best set of markers described to date for the identification of MSI
tumours, regardless of their MMR defect. Moreover, matching
normal DNA is not mandatory in most cases. The superior
performance of the pentaplex assay over the NCI panel is
particularly evident for tumours with defective MSH6 and for
endometrial cancer samples. For rare cases that display borderline
instability and for which normal matching DNA is not available,
the total size of PCR products for the five markers can be
compared with the TVR obtained from unrelated normal DNA.
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